A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

NCT07157033 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreas Cancer
Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: XER-001

Sponsor

Xerient Pharma